Regeneron Pharmaceuticals (NASDAQ:REGN) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate ...

Regeneron (REGN) came out with quarterly earnings of $8.22 per share, missing the Zacks Consensus Estimate of $8.43 per share. This compares to earnings of $9.55 per share a year ago. These ...

Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Regeneron holds exclusive U.S. rights ... gaining an additional 0.51% on the Nasdaq Global Select Market. The views and opinions expressed herein are the views and opinions of the author and ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the upcoming presentation of 27 abstracts, including eight oral presentations on EYLEA HD (aflibercept) Injection 8 mg in wet age ...

Regeneron Pharmaceuticals earnings at a glance ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Regeneron (REGN) reported $3.03 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.7%. EPS of $8.22 for the same period compares to $9.55 a year ago.

Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak ...

Regeneron (REGN) stock drops as the company's Q1 2025 results miss forecasts amid disappointing sales from its blockbuster ...

(RTTNews) - Regeneron Pharmaceuticals ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Sales of Regeneron’s lead drug, Eylea, which is approved for various ophthalmology indications, are likely to have declined in the first quarter owing to competition from Vabysmo. To counter the ...